Abstract: A display device includes a substrate, a first display element which is disposed on the substrate, and a plurality of diffraction patterns which are disposed on a path of light emitted from the first display element and arranged along a direction with a first period. when a width of a cross section of one of the plurality of diffraction patterns is defined as a first length, the first period and the first length satisfy Inequality (1): 0.4 ? d ? 1 / DP ? 1 ? 1 , ( 1 ) where DP1 is the first period, and d1 is the first length.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

Abstract: Provided concerns a blood biomarker for discerning the cerebral deposition of amyloid beta, which is a causative material of Alzheimer's dementia. A marker according to the subject matter can conveniently and rapidly predictive of cerebral amyloid beta accumulation by use of a blood and can be effectively used in diagnosing relevant diseases including mild cognitive impairment at a preclinical level.

Abstract: Provided is a method for quantifying A? in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological A? accumulation occur. Through cut-off values of measured values measured by the method for quantifying A? according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of A? in the brain occurs, and it is possible to predict progression to AD.

Abstract: Provided is a method for quantifying A? in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological A? accumulation occur. Through cut-off values of measured values measured by the method for quantifying A? according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of A? in the brain occurs, and it is possible to predict progression to AD.